Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

被引:6
|
作者
Perrillo, Robert P. [1 ]
Marcellin, Patrick [2 ]
机构
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] Hop Beaujon, Dept Hepatol, Clichy, France
关键词
POSITIVE CHRONIC HEPATITIS; TENOFOVIR DISOPROXIL FUMARATE; NUCLEOSIDE-NAIVE PATIENTS; VIRUS POLYMERASE MUTATIONS; LONG-TERM THERAPY; ADV SWITCH DATA; ADEFOVIR DIPIVOXIL; E-ANTIGEN; LAMIVUDINE THERAPY; DNA REDUCTION;
D O I
10.3851/IMP1482
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Long-term therapy with oral nucleoside/nucleotide analogues (NAs) is a favoured approach to the treatment of patients with chronic hepatitis B (CHB); however, all oral agents currently approved for the treatment of such patients are associated with some risk for drug resistance. This can lead to a rebound in HBV levels and, eventually, progressive liver disease. Combination therapy is one strategy that has the potential for enhanced antiviral effects and diminished or delayed resistance. The disadvantages of combination therapy include increased cost, the potential for drug interactions and increased toxicity. Additional therapeutic efficacy from combination therapy has not been demonstrated in clinical trials of HBV, and this approach might be less relevant now that potent NAs with excellent drug resistance profiles are available. However, it might be possible to identify subsets of patients (for example, those with extremely high viraemia or low baseline alanine aminotransferase levels) who derive added benefit from combination therapy. This review examines efficacy and resistance data for new low resistance oral NAs and clinical experience to date with de novo combination therapy in patients with CHB. The application of combination therapy in select populations of patients with CHB is also discussed.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 50 条
  • [31] New developments in antiviral therapy for chronic hepatitis B
    Takkenberg, R. B.
    Weegink, C. J.
    Zaaijer, H. L.
    Reesink, H. W.
    VOX SANGUINIS, 2010, 98 (04) : 481 - 494
  • [32] The current status of antiviral therapy of chronic hepatitis B
    Asselah, Tarik
    Ripault, Marie-Pierre
    Castelnau, Corinne
    Giuily, Nathalie
    Boyer, Nathalie
    Marcellin, Patrick
    JOURNAL OF CLINICAL VIROLOGY, 2005, 34 : S115 - S124
  • [33] The Fate of Chronic Hepatitis B in the Era of Antiviral Therapy
    Park, Yoon Hea
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Seung Up
    Kim, Do Young
    Kim, Ja Kyung
    Lee, Kwan Sik
    Han, Kwang-Hyub
    Chon, Chae Yoon
    Ahn, Sang Hoon
    HEPATOLOGY, 2012, 56 : 364A - 364A
  • [34] Current antiviral therapy for chronic hepatitis B in Japan
    Ide, Tatsuya
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A60 - A60
  • [35] When to Stop Antiviral Therapy in Chronic Hepatitis B
    Tekin, Suda
    KLIMIK JOURNAL, 2019, 32 (01) : 4 - 7
  • [36] Current Trend in Antiviral Therapy for Chronic Hepatitis B
    Chien, Rong-Nan
    Liaw, Yun-Fan
    VIRUSES-BASEL, 2022, 14 (02):
  • [37] Antiviral therapy in patients with chronic hepatitis B and cirrhosis
    Lai, CJ
    Terrault, NA
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (03) : 629 - +
  • [39] IMMUNOMODULATORY AND ANTIVIRAL THERAPY IN CHRONIC B-HEPATITIS
    OKUDA, K
    OMATA, M
    DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (10) : S500 - S500
  • [40] Discontinuation of antiviral therapy in chronic hepatitis B patients
    Medas, Renato
    Liberal, Rodrigo
    Macedo, Guilherme
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (24) : 6979 - 6986